TABLE 3.
Examples of annual costs and of cost savings after implementation of the program ($)
| Before (1991) | After (1994) | Cost reduction ($) | |||
|---|---|---|---|---|---|
| Therapeutic interchange | |||||
| Cefotaxime/ceftriaxone | 75,767 | 36,142 | 39,625 | ||
| Cefoxitin/cefotetan | 48,981 | 28,333 | 20,648 | ||
| Tobramycin/gentamicin | 97,285 | 61,356 | 35,929 | ||
| Restricted IV antibiotics | |||||
| Ceftazidime | 309,675 | 180,091 | 129,584 | ||
| Vancomycin | 218,337 | 212,481 | 5,856 | ||
| Imipenem | 175,492 | 139,967 | 35,525 | ||
| IV to oral | |||||
| Metronidazole | 14,894 | 13,405 | 1,489 | ||
| Cotrimoxazole | 9,916 | 7,370 | 2,546 | ||
IV Intravenous